Articles related to HEART FAILURE (HF)

FRESH-UP found no benefit in health status, hospitalizations, or mortality when restricting fluids to 1,500 mL daily in stable heart failure patients, while significantly increasing thirst distress.

Community-based centers with limited resources should identify an on-site clinician to serve as their ‘shock champion’ as well as a center providing advanced heart failure therapies to partner with on complex CS cases.

In this comprehensive analysis of 2,853 TTS patients, beta-blocker therapy demonstrated a significant 29% reduction in mortality risk during follow-up, particularly within the first year after discharge.

Digoxin’s narrow therapeutic window and individual patient variability necessitate careful monitoring and consideration in clinical practice.

The bRIGHT study demonstrates that T-TEER using the TriClip system can lead to sustained TR reduction and quality of life improvements in a diverse, real-world population with advanced tricuspid valve disease.

Rapid optimization of guideline-directed medical therapy in heart failure patients post-discharge was associated with sustained decongestion and improved clinical outcomes at 90 days.